CLDN9: Another Key Regulator for Tumors or Hearing Loss from the CLDN Family!Presently, ample research suggested that CLDN family members are partly responsible for the development and progression of various malignancies, making them promising target candidates for cancer therapy. For example, CL...
Detailed information

CLDN6: A "New Favorite" in Targeted Cancer Therapy after CLDN 18.2!Lately, the 2022-AACR conference saw the emergence of numerous potential innovative targets. CLDN6 is one of them. The companies such as BioNTech, Amgen, and IMAB have disclosed the progress of CLDN6 targets in their pip...
Detailed information

Recombinant Monkeypox Virus Proteins - Accelerate Monkeypox ResearchThe World Health Organization (WHO) declared the 2022 monkeypox outbreak a Public Health Emergency of International Concern (PHEIC) on 23 July 2022 local time [1]. On July 27, the WHO reported more than 18,000 cases of m...
Detailed information

SSTR2: A Prominent Target in SSTR Family, Offers a More Precise Therapy in Neuroendocrine Tumors (NET)The 19th Annual Meeting of the European Neuroendocrine Tumor Society (ENETS) was held in Barcelona from Mar 10-11, 2022. ENETS is the highest level academic meeting in the field of neuroendocrine tumors (NET) diagnosis a...
Detailed information

SEMA4D/CD100: As an Important Immunoregulator to Improve ImmunotherapyIn April 2022, the American Association for Cancer Research (AACR) annual meeting announced phase 1b/2 clinical data (NCT04815720) for Pepinemab, the first SEMA4D-targeted antibody for the treatment of recurrent or metas...
Detailed information

GUCY2C: a Novel Target in Tumor Immunotherapy, Specially in Colorectal Cancer CAR T Therapy!On April 19, 2022, Innovative Cellular Therapeutics (ICT) company from Shanghai, China receives FDA Fast Track Designation for GCC19CART. GCC19CART is a CAR-T cell therapy based on ICT's unique CoupledCAR® technology pl...
Detailed information

ROR1, an Emerging Target for Tumor ImmunotherapyIn 2020, the ROR1 target is favored by pharmaceutical giants such as Merck & Co., CStone Pharmaceuticals, etc. On October 29, 2020, Cstone Pharmaceuticals announced that it has reached a licensing agreement with Lego...
Detailed information

TFPI: a Natural Anticoagulant Protein, Future Therapies for HemophiliaEvery year, April 17 is observed as World Hemophilia Day. 17th April 2022 marks the observance of the 34rd World Hemophilia Day. Hemophilia is a general term for a group of rare bleeding disorders caused by an inherited ...
Detailed information

TTR: an Important Protein of Amyloidosis, Novel Therapies are Upcoming for Rare Diseases ATTR-CM and ATTR-PN!AstraZeneca and Neurimmune Therapeutics have signed an agreement on Mar. 1, 2022, contributing about $700 million cooperation on NI006 clinical research. NI006 is a transthyretin (TTR) targeting modulator for rare diseas...
Detailed information

DT3C, a Powerful Tool for ADC Drug Internalization In VitroIn 2014, MikiYamaguchi et al. produced a recombinant protein through gene recombination technology, which is a tool to evaluate more precisely the efficiency of mAbs' internalization by cells. The protein includes a diph...
Detailed information